Consolidated Planning Corp Raises Stake in Novo Nordisk A/S (NYSE:NVO)

Consolidated Planning Corp lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% in the fourth quarter, Holdings Channel reports. The firm owned 56,163 shares of the company’s stock after purchasing an additional 431 shares during the period. Novo Nordisk A/S makes up about 1.1% of Consolidated Planning Corp’s investment portfolio, making the stock its 25th biggest position. Consolidated Planning Corp’s holdings in Novo Nordisk A/S were worth $5,810,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. Pacific Center for Financial Services lifted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after buying an additional 141 shares during the last quarter. Bell Investment Advisors Inc lifted its stake in Novo Nordisk A/S by 79.9% in the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the last quarter. CNB Bank bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $26,000. Finally, Citizens National Bank Trust Department lifted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after buying an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective on the stock. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Price Performance

NYSE:NVO traded up $1.06 during mid-day trading on Friday, reaching $126.85. 3,312,457 shares of the stock were exchanged, compared to its average volume of 3,307,405. The business has a fifty day moving average price of $126.86 and a 200 day moving average price of $111.98. The firm has a market capitalization of $569.24 billion, a PE ratio of 46.90, a PEG ratio of 2.10 and a beta of 0.41. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Research analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.